News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Real-time Estimate Cboe BZX Other stock markets 03:03:08 2024-04-25 pm EDT			5-day change	1st Jan Change
149.6 ^USD	+3.83%		+13.50%	-16.96%

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	Apr. 24	BU
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23	MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	Apr. 23	DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	Apr. 23	MT
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	BU
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	CI
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
BeiGene, Ltd. Announces Executive Changes	Mar. 20	CI
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	Mar. 15	AQ
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	Mar. 14	MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients	Mar. 14	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Summary

Filters